Heart HealthResearch PaperPaywall

HDAC3 switches on an artery-wall inflammasome that drives plaque buildup in mice

Blocking the enzyme HDAC3 in artery-lining cells reduced NLRP3 inflammasome activity and plaque in atherosclerosis-prone mice. Human data are limited to expression.

Sunday, November 22, 2026 0 views
Published in Cell Death Differ
a mouse aorta cross-section stained red showing plaque, on a microscope slide under a lab microscope

Summary

Artery plaque is driven in part by inflammation in the cells lining blood vessels. This study points to an enzyme called HDAC3 as a switch for that inflammation. In human plaque cell data, HDAC3 and an inflammatory complex called NLRP3 were both elevated in inflamed endothelial cells from patients with symptoms. In atherosclerosis-prone mice, deleting HDAC3 only in the vessel lining reduced plaque, lipid deposits and NLRP3 activation. A drug that inhibits HDAC3 also reduced plaque in these mice. In cultured human vein cells, HDAC3 removed a chemical tag (acetylation) from a gene-regulating protein called SP1, which helped SP1 turn on the NLRP3 gene. This is a mechanism finding in mice and cells, with human evidence limited to gene expression. No human trial of HDAC3 inhibition for plaque was reported, and the abstract does not address lifespan or human function.

0:00--:--

Detailed Summary

Atherosclerosis, the plaque buildup that underlies heart attack and stroke, is increasingly understood as an inflammatory disease as well as a cholesterol disease. Inflammation in the endothelium, the thin cell layer lining arteries, is an early and important driver. Understanding what switches that inflammation on matters for cardiovascular aging.

This study examined HDAC3, an epigenetic enzyme that removes acetyl tags from proteins, and its link to the NLRP3 inflammasome, an inflammatory sensor complex. The team analyzed single-cell transcriptomic data from plaques of symptomatic patients, used endothelial-specific HDAC3 knockout in ApoE-/- mice (a standard atherosclerosis model), tested an HDAC3 inhibitor in those mice, and ran inhibitor and overexpression experiments in human umbilical vein endothelial cells (HUVECs).

In human plaque data, HDAC3 and NLRP3 expression were elevated in inflammatory endothelial cells from symptomatic patients. In mice, endothelial HDAC3 knockout reduced lesion size, lipid deposition and endothelial NLRP3 inflammasome activation versus controls. In HUVECs, HDAC3 boosted NLRP3 transcription through the NF-kB pathway, promoting inflammasome activation and cell injury. The mechanism: HDAC3 lowered acetylation of SP1 at lysine 703, increasing SP1 binding to the NLRP3 promoter and driving its transcription. Pharmacological HDAC3 inhibition reduced endothelial inflammation, raised SP1 acetylation and lessened atherosclerosis in ApoE-/- mice.

Together, the work lays out a chain from HDAC3 to SP1 deacetylation to NLRP3 transcription to endothelial inflammation to plaque. It supports HDAC3 as a candidate therapeutic target and shows the mechanism can be modified pharmacologically in a mouse model.

Caveats are important. The human evidence is expression data only, so it shows association, not that HDAC3 causes plaque in people. Everything causal comes from mice and cultured cells. The abstract does not report sample sizes, safety or toxicity of HDAC3 inhibition, effects on lifespan, or any human function outcome. This summary rests on the abstract alone.

Key Findings

  • Single-cell data showed higher HDAC3 and NLRP3 in inflammatory endothelial cells of plaques from symptomatic patients (association only).
  • Endothelial-specific HDAC3 knockout in ApoE-/- mice reduced lesion size, lipid deposition and endothelial NLRP3 inflammasome activation.
  • In HUVECs, HDAC3 reduced SP1 Lys-703 acetylation, increasing SP1 binding to the NLRP3 promoter and NLRP3 transcription.
  • An HDAC3 inhibitor lessened atherosclerosis and raised SP1 acetylation in ApoE-/- mice; lifespan and safety were not reported in the abstract.

Methodology

The study combined human plaque single-cell transcriptomic analysis, endothelial-specific HDAC3 knockout in ApoE-/- mice, pharmacological HDAC3 inhibition in the same model, and inhibitor and overexpression experiments in HUVECs. Mechanistic steps involved SP1 acetylation at Lys-703 and SP1 binding to the NLRP3 promoter. Animal work was ethics-approved; the authors declared no competing interests.

Study Limitations

This summary is based on the abstract only, so sample sizes, statistics and safety data were unavailable. Causal evidence comes from one mouse model and cultured human vein cells; human data are expression-level associations. Effects of HDAC inhibition outside the endothelium, long-term safety, and lifespan or functional outcomes were not reported.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: